Why did Active Biotech fall on 6 October?
Written after the close on
Active Biotech −3.78%
Active Biotech fell clearly despite a Japanese patent win. Over the last five trading days Active Biotech fell clearly while the OMX Stockholm 30 was roughly unchanged, so the drop was specific to the company rather than the market. The main news was a Japanese patent grant for an eye-drop formulation of laquinimod, its clinical drug candidate for severe inflammatory eye diseases such as non-infectious uveitis (inflammation inside the eye), giving intellectual-property protection and potential market exclusivity in Japan until 2042. That is a positive long-term milestone, so the decline likely reflects profit-taking after the news or disappointment that a patent, unlike a trial result or partnership, brings no near-term revenue. Watch for further patent grants or partnership news on laquinimod, which is what usually moves a small clinical-stage biotech.